Related references
Note: Only part of the references are listed.Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
European Society for Medical Oncology (ESMO) position paper on supportive and palliative care
K. Jordan et al.
ANNALS OF ONCOLOGY (2018)
Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature
L. Spain et al.
ANNALS OF ONCOLOGY (2017)
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma
Teresa M. Petrella et al.
EUROPEAN JOURNAL OF CANCER (2017)
Immune checkpoint inhibitors and elderly people: A review
Amaury Daste et al.
EUROPEAN JOURNAL OF CANCER (2017)
The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials
Marco Donia et al.
EUROPEAN JOURNAL OF CANCER (2017)
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
Ethan Basch et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Follow-up care of cancer survivors: challenges and solutions
Linda A. Jacobs et al.
LANCET ONCOLOGY (2017)
Defining cancer survivors, their needs, and perspectives on survivorship health care in the USA
Deborah K. Mayer et al.
LANCET ONCOLOGY (2017)
Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings
Gary X. Wang et al.
RADIOGRAPHICS (2017)
Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists
Frederic Illouz et al.
CANCER MEDICINE (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Comprehensive Geriatric Assessment in the Older Adult with Cancer: A Review
Catalina Hernandez Torres et al.
EUROPEAN UROLOGY FOCUS (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Effect of nivolumab on health-related quality of life in patients with treatment-na⟨ve advanced melanoma: results from the phase III CheckMate 066 study
G. V. Long et al.
ANNALS OF ONCOLOGY (2016)
Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab
Lauren M. Kropp et al.
JOURNAL OF IMMUNOTHERAPY (2016)
The development of immunotherapy in older adults: New treatments, new toxicities?
Carole Helissey et al.
JOURNAL OF GERIATRIC ONCOLOGY (2016)
Immune Checkpoint Inhibitors in Older Adults
Rawad Elias et al.
CURRENT ONCOLOGY REPORTS (2016)
KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.
Adil Daud et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Society for Melanoma Research 2015 Congress
Pigment Cell & Melanoma Research (2015)
Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
Alexander T. Faje et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Short Form 36 (SF-36) Health Survey Questionnaire: normative data for Wales
Vanessa Burholt et al.
JOURNAL OF PUBLIC HEALTH (2011)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Share Paper
